Surgical treatment of liver metastases from non-colorectal non-neuroendocrine carcinomas

• Published in: Journal of cancer research and clinical oncology 2022-02, Vol.148 (2), p.503-515
• Main Authors: Bauschke, Astrid, Altendorf-Hofmann, Annelore, Homman, Merten, Manger, Thomas, Pertschy, Jörg, Helfritzsch, Herry, Göbel, Hubert, Settmacher, Utz
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Breast cancer; Cancer Research; Classification; Colorectal carcinoma; Female; Germany - epidemiology; Hematology; Hepatectomy - methods; Hepatectomy - mortality; Hepatectomy - trends; History, 20th Century; History, 21st Century; Humans; Internal Medicine; Kidney cancer; Kidneys; Liver; Liver Neoplasms - diagnosis; Liver Neoplasms - mortality; Liver Neoplasms - secondary; Liver Neoplasms - surgery; Lymph nodes; Lymphatic system; Male; Medical prognosis; Medicine; Medicine & Public Health; Metastases; Metastasis; Middle Aged; Neuroendocrine tumors; Oncology; Original Article – Clinical Oncology; Original – Clinical Oncology; Patients; Prognosis; Retrospective Studies; Risk factors; Statistical analysis; Survival; Survival Analysis; Treatment Outcome; Tumors
• ISSN: 0171-5216; 1432-1335
• DOI: 10.1007/s00432-021-03631-5

Introduction In the literature, results after surgical treatment of non-colorectal non-neuroendocrine liver metastases (NCNNLM) are reported that are often inferior to those from colorectal liver metastases. The selection of patients with favorable tumor biology is currently still a matter of discussion. Materials/methods The retrospective data analysis was based on data that were collected for the multicenter study “Role of surgical treatment for non-colorectal liver metastases” in county Thuringia. Results For the study, 637 patients were included from 1995 to 2018. 5 and 10-year survival of R0 resected patients were 33% and 19%, respectively. In the multi-variate analysis of the entire group, sex, timing, disease-free interval, number of metastases, R-classification as well as lymph node status of the primary lesion showed an independent statistical influence on the 5-year survival. In the group of R0 resected patients, disease-free interval, number of metastases and lymph node status of the primary lesion influenced the 5-year survival in the multi-variate analysis. In kidney malignancies, R-classification, timing and number of liver metastases were statistically significant in the multi-variate analysis of the 5-year survival, in mamma carcinomas only the R-classification. Conclusion The Adam score identifies some risk factors which influence prognosis in most but not in all tumor entities. For kidney cancer and breast cancer it can be simplified.